Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial.
Adam R Brentnall, Matejka Rebolj, Peter Sasieni et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial analyzed the impact of age on prostate cancer overdiagnosis using long-term follow-up data from the CAP trial. Among 189,386 men invited for PSA testing, the cumulative incidence of prostate cancer at 15 years was 7.08% in the screening group versus 6.94% in the control group, indicating an absolute excess incidence of 0.14%. The study highlights that overdiagnosis increases significantly with age due to competing mortality.
Key findings
- Cumulative incidence of prostate cancer at 15 years was 7.08% in the screening group.
- Absolute excess incidence difference was 0.14% between screening and control groups.
- The chance of overdiagnosis increased to 58% for men diagnosed at age 80.
Why it matters
Understanding the dynamics of prostate cancer overdiagnosis is crucial for clinicians, as it informs screening practices and helps balance the benefits and harms of early detection, particularly in older populations.